Welcome to MolDiag-PaCa

1. Andren-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the new millennium Pancreatology. 2002; 2: 431-9.

2. Bramhall, S. R., W. H. Allum, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-5.

3. Greenlee, R. T., M. B. Hill-Harmon, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36 128

4. Heinmöller E, Dietmaier W, Zirngibl H, Heinmöller P, Scaringe W, Jauch K-W, Hofstadter F, Ruschoff J. 2000. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 157:83–92.

5. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, and Offerhaus GJ. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25: 579-586.

6. Luttges J et al. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities. (2001) Dig Dis 19: 15-23.

7. Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, and Hahn SA. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001, 158: 1677-1683.

8. Moskaluk CA, Hruban RH, and Kern SE. p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Research 1997, 57: 2140-2143.

9. Mueller F et al. KOC is a novel molecular indicator of malignancy. Br J Cancer 88: 699-701 (2003).

10. Neoptolemos JP et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomised controlled trial. Ann Surg 2001b; 234:758-768.

11. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585.

12. Neoptolemos JP et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.

13. Parkin, D. M., F. I. Bray, et al. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8: 4-66.

14. Saad, SD, Hoff, PM Molecular-Targeted Agents in Pancreatic Cancer Cancer Control: 11, 32-39, 2004

15. Sener, S. F., A. Fremgen, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 1999; 189: 1-7.

16. Shore S, Raraty M, Ghaneh P, et al. Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther. 2003; 18:1049-1069.

17. Silvermann DT, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994, 86: 1510-1516.

18. Sohn, T. A., C. J. Yeo, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-79.

19. Vimalachandran, D, Ghaneh,P., Costello,E., Neoptolemos,JP. Genetics and Prevention of Pancreatic Cancer. Cancer Control 11, 6-14, 2004.

20. Yamano, M, Fujii, H., Takagaki, T., Kadowaki, N., Watanabe, H., Sjirai, T. Genetic Progression and Divergence in Pancreatic Carcinoma. Am J Path  2000; 156:2123-2133

21. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M, and Yeo CJ. Pancreatic cancer. Curr Probl Cancer 2002, 26: 176-275. 133